Related Funding Opportunities

  • PAR-20-295, Clinical Translation of Activated Optical Fluorescence Methods and Technologies for Sensitive Cancer Detection in Vivo (R01 Clinical Trial Optional)
  • NOT-CA-21-008, Availability of Administrative Supplements to Adapt/Repackage Visualization Methods for Enhancing Cancer Moonshot Data
  • NOT-CA-21-068, Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
  • NOT-CA-21-069, Coordinating Center for Canine Cancer Immunotherapy Network (K9CIN; U24 Clinical Trial Not Allowed)
  • NOT-CA-21-097, Notice of Pre-application Webinar for Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
  • RFA-CA-21-037, 3D Technologies to Accelerate HTAN Atlas Building Efforts (UH2 Clinical Trial Not Allowed)
  • RFA-CA-21-041, Pancreatic Ductal Adenocarcinoma (PDAC) Stromal Reprogramming Consortium (PSRC) (U01 Clinical Trial Not Allowed)
  • RFA-CA-21-042, Pancreatic Ductal Adenocarcinoma Stromal Reprogramming Consortium Coordinating and Data Management Center (PSRC CDMC) (U24 Clinical Trial Not Allowed)
  • RFA-CA-21-050, Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)
  • RFA-CA-21-051, Coordinating Center for Canine Cancer Immunotherapy Network (K9CIN; U24 Clinical Trial Not Allowed)
  • RFA-CA-19-049, Revision Applications for Mechanisms of Cancer Drug Resistance (R01 Clinical Trial Not Allowed)
  • RFA-CA-19-050, Revision Applications for Mechanisms of Cancer Drug Resistance (U01 Clinical Trial Not Allowed)
  • RFA-CA-19-051, Revision Applications for Mechanisms of Cancer Drug Resistance (U54 Clinical Trial Not Allowed)
  • RFA-CA-19-052, Revision Applications for Mechanisms of Cancer Drug Resistance (P01 Clinical Trial Not Allowed)
  • RFA-CA-19-053, Revision Applications for Mechanisms of Cancer Drug Resistance (P50 Clinical Trial Not Allowed)